PH12013500454A1 - Substituted imidazopyridazines - Google Patents

Substituted imidazopyridazines

Info

Publication number: PH12013500454A1
Authority: PH; Philippines
Prior art keywords: compounds; substituted; substituted imidazopyridazines; imidazopyridazines; hyper
Prior art date: 2010-09-10

Application number

PH1/2013/500454A

Other languages

English (en)

Inventor

Rolf Bohlmann

Rolf Jautelat

Ulrich Klar

Marcus Koppitz

Dirk Kosemund

Philip Lienau

Gerhard Siemeister

Antje Margret Wengner

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-10

Filing date

2011-09-06

Publication date

2013-04-29

2011-09-06 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2013-04-29 Publication of PH12013500454A1 publication Critical patent/PH12013500454A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Paper (AREA)
Cosmetics (AREA)

PH1/2013/500454A 2010-09-10 2011-09-06 Substituted imidazopyridazines PH12013500454A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP10176134		2010-09-10
EP11075022		2011-02-04
EP11170775		2011-06-21
EP11170771		2011-06-21
PCT/EP2011/065368 WO2012032031A1 (en)	2010-09-10	2011-09-06	Substituted imidazopyridazines

Publications (1)

Publication Number	Publication Date
PH12013500454A1 true PH12013500454A1 (en)	2013-04-29

Family

ID=44545741

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH1/2013/500454A PH12013500454A1 (en)	2010-09-10	2011-09-06	Substituted imidazopyridazines

Country Status (38)

Country	Link
US (1)	US9255100B2 (es)
EP (1)	EP2614063B1 (es)
JP (1)	JP5824050B2 (es)
KR (1)	KR20140032337A (es)
CN (1)	CN103370318B (es)
AP (1)	AP3607A (es)
AR (1)	AR082946A1 (es)
AU (1)	AU2011298844B2 (es)
BR (1)	BR112013005679A2 (es)
CA (1)	CA2810755A1 (es)
CO (1)	CO6720961A2 (es)
CR (1)	CR20130102A (es)
CU (1)	CU24187B1 (es)
CY (1)	CY1117352T1 (es)
DK (1)	DK2614063T3 (es)
DO (1)	DOP2013000054A (es)
EA (1)	EA023420B1 (es)
EC (1)	ECSP13012752A (es)
ES (1)	ES2568220T3 (es)
HR (1)	HRP20160360T1 (es)
HU (1)	HUE028771T2 (es)
IL (1)	IL225058A (es)
MA (1)	MA34516B1 (es)
ME (1)	ME02389B (es)
MX (1)	MX2013002713A (es)
MY (1)	MY185139A (es)
NZ (1)	NZ607904A (es)
PE (1)	PE20131164A1 (es)
PH (1)	PH12013500454A1 (es)
PL (1)	PL2614063T3 (es)
RS (1)	RS54661B1 (es)
SA (1)	SA111320735B1 (es)
SG (1)	SG188417A1 (es)
SI (1)	SI2614063T1 (es)
TW (1)	TWI541243B (es)
UY (1)	UY33598A (es)
WO (1)	WO2012032031A1 (es)
ZA (1)	ZA201301756B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI541243B (zh)	2010-09-10	2016-07-11	拜耳知識產權公司	經取代咪唑并嗒
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9416132B2 (en)	2011-07-21	2016-08-16	Tolero Pharmaceuticals, Inc.	Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
US9512126B2 (en)	2012-03-14	2016-12-06	Bayer Intellectual Property Gmbh	Substituted imidazopyridazines
PE20190736A1 (es)	2012-06-13	2019-05-23	Incyte Holdings Corp	Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
WO2014020041A1 (en)	2012-08-02	2014-02-06	Bayer Pharma Aktiengesellschaft	Combinations for the treatment of cancer
WO2014020043A1 (en)	2012-08-02	2014-02-06	Bayer Pharma Aktiengesellschaft	Combinations for the treatment of cancer
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
JP6377068B2 (ja)	2012-11-16	2018-08-22	ユニバーシティ・ヘルス・ネットワーク	ピラゾロピリミジン化合物
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
TW201437211A (zh) *	2013-03-01	2014-10-01	Bayer Pharma AG	經取代咪唑并嗒□
KR102269032B1 (ko)	2013-04-19	2021-06-24	인사이트 홀딩스 코포레이션	Fgfr 저해제로서 이환식 헤테로사이클
PT3008062T (pt)	2013-06-11	2017-06-07	Bayer Pharma AG	Derivados de profármaco de triazolopiridinas substituídas
TN2015000544A1 (en) *	2013-06-13	2017-04-06	Bayer Pharma AG	Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer
CN103360399B (zh) *	2013-08-02	2016-03-02	北京大学	6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
GB201321734D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic Agents
CA2940237C (en) *	2014-02-21	2023-03-07	Frost Biologic, Inc.	Antimitotic amides for the treatment of cancer and proliferative disorders
WO2015157955A1 (en)	2014-04-17	2015-10-22	Abbvie Inc.	Heterocyclic btk inhibit ors
TW201613927A (en)	2014-09-01	2016-04-16	Bayer Pharma AG	Method for preparation of substituted imidazopyridazines
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
ES2895769T3 (es)	2015-02-20	2022-02-22	Incyte Corp	Heterociclos bicíclicos como inhibidores de FGFR
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2981844A1 (en)	2015-04-17	2016-10-20	Netherlands Translational Research Center B.V.	Prognostic biomarkers for ttk inhibitor chemotherapy
WO2016187028A1 (en) *	2015-05-15	2016-11-24	Celgene Avilomics Research, Inc.	Heteroaryl compounds, synthesis thereof, and intermediates thereto
EP3383796B1 (en) *	2015-12-04	2020-09-16	ExxonMobil Research and Engineering Company	Emm-28, a novel synthetic crystalline material, its preparation and use
WO2018013430A2 (en)	2016-07-12	2018-01-18	Arisan Therapeutics Inc.	Heterocyclic compounds for the treatment of arenavirus infection
FI3484888T5 (fi) *	2016-07-18	2024-02-26	Univ Health Network	Ttk:n estäjän kiinteitä muotoja
EP3609547B1 (en) *	2017-04-11	2021-10-06	Straumann Holding AG	Dental implant
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SI3788047T1 (sl)	2018-05-04	2024-11-29	Incyte Corporation	Trdne oblike inhibitorja fgfr in postopki priprave le-teh
SG11202010882XA (en)	2018-05-04	2020-11-27	Incyte Corp	Salts of an fgfr inhibitor
JP7235047B2 (ja)	2018-05-08	2023-03-08	日本新薬株式会社	アザベンゾイミダゾール化合物及び医薬
US12419865B2 (en)	2018-12-06	2025-09-23	Arisan Therapeutics Inc.	Compounds for the treatment of arenavirus infection
CA3127502A1 (en)	2019-02-12	2020-08-20	Sumitomo Dainippon Pharma Oncology, Inc.	Formulations comprising heterocyclic protein kinase inhibitors
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
CN111978325B (zh) *	2019-05-22	2023-11-17	中国药科大学	咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en)	2019-10-14	2023-03-21	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Derivatives of an fgfr inhibitor
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2022221170A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261160A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
CA3241213A1 (en) *	2021-12-15	2023-06-22	Heidi Lane	Pharmaceutical combinations for use in the treatment of neoplastic diseases
KR20250158017A (ko) *	2023-01-19	2025-11-05	스카이호크 테라퓨틱스, 인코포레이티드	스플라이싱 조절에 유용한 조성물

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2263566C (en)	1996-08-28	2003-09-09	Pfizer Inc.	Substituted 6,5-hetero-bicyclic derivatives
ES2244613T3 (es)	2000-04-27	2005-12-16	Astellas Pharma Inc.	Derivados de imidazopiridina.
US7132426B2 (en)	2003-07-14	2006-11-07	Arena Pharmaceuticals, Inc.	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
CA2555263A1 (en)	2004-02-12	2005-09-01	Neurogen Corporation	Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
US7306631B2 (en)	2004-03-30	2007-12-11	The Procter & Gamble Company	Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2007025090A2 (en)	2005-08-25	2007-03-01	Kalypsys, Inc.	Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US20070078136A1 (en) *	2005-09-22	2007-04-05	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en)	2005-09-22	2010-05-25	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful as kinase modulators
AR056785A1 (es) *	2005-11-10	2007-10-24	Schering Corp	COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS
TW200840584A (en) *	2006-12-26	2008-10-16	Gilead Sciences Inc	Pyrido(3,2-d)pyrimidines useful for treating viral infections
US8546394B2 (en) *	2007-04-17	2013-10-01	Bristol-Myers Squibb Company	Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
WO2009060197A1 (en)	2007-11-08	2009-05-14	Centro Nacional De Investigaciones Oncologicas (Cnio)	Imidazopyridazines for use as protein kinase inhibitors
CN101981033B (zh)	2008-02-06	2015-02-04	百时美施贵宝公司	用作激酶抑制剂的取代的咪唑并哒嗪化合物
TWI491610B (zh)	2008-10-09	2015-07-11	必治妥美雅史谷比公司	作為激酶抑制劑之咪唑并嗒腈
WO2010088518A2 (en)	2009-01-31	2010-08-05	Kalypsys, Inc.	Heterocyclic modulators of gpr119 for treatment of disease
CA2760077A1 (en) *	2009-04-29	2010-11-04	Marcus Koppitz	Substituted imidazoquinoxalines
TW201107329A (en) *	2009-07-30	2011-03-01	Oncotherapy Science Inc	Fused imidazole derivative having ttk inhibitory action
CN102596932A (zh)	2009-09-04	2012-07-18	拜耳医药股份有限公司	作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
EP2343297A1 (en)	2009-11-30	2011-07-13	Bayer Schering Pharma AG	Triazolopyridines
EP2343295A1 (en)	2009-11-30	2011-07-13	Bayer Schering Pharma AG	Triazolopyridine derivates
EP2343294A1 (en)	2009-11-30	2011-07-13	Bayer Schering Pharma AG	Substituted triazolopyridines
CA2793279A1 (en)	2010-03-18	2011-09-22	Ulrich Klar	Imidazopyrazines
JP5824040B2 (ja)	2010-06-01	2015-11-25	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換イミダゾピラジン
TWI541243B (zh)	2010-09-10	2016-07-11	拜耳知識產權公司	經取代咪唑并嗒
WO2012080230A1 (en)	2010-12-17	2012-06-21	Bayer Pharma Aktiengesellschaft	6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP5822944B2 (ja)	2010-12-17	2015-11-25	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン
WO2012080234A1 (en)	2010-12-17	2012-06-21	Bayer Pharma Aktiengesellschaft	Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080236A1 (en)	2010-12-17	2012-06-21	Bayer Pharma Aktiengesellschaft	6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US9212184B2 (en)	2010-12-17	2015-12-15	Bayer Intellectual Property Gmbh	6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors
CA2821829A1 (en)	2010-12-17	2012-06-21	Bayer Intellectual Property Gmbh	Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

2011
- 2011-08-25 TW TW100130542A patent/TWI541243B/zh not_active IP Right Cessation
- 2011-09-06 KR KR1020137009011A patent/KR20140032337A/ko not_active Ceased
- 2011-09-06 AU AU2011298844A patent/AU2011298844B2/en not_active Ceased
- 2011-09-06 ME MEP-2016-63A patent/ME02389B/me unknown
- 2011-09-06 EA EA201390339A patent/EA023420B1/ru not_active IP Right Cessation
- 2011-09-06 WO PCT/EP2011/065368 patent/WO2012032031A1/en not_active Ceased
- 2011-09-06 CN CN201180054217.5A patent/CN103370318B/zh not_active Expired - Fee Related
- 2011-09-06 DK DK11751910.8T patent/DK2614063T3/en active
- 2011-09-06 SG SG2013016480A patent/SG188417A1/en unknown
- 2011-09-06 SI SI201130761A patent/SI2614063T1/sl unknown
- 2011-09-06 MA MA35720A patent/MA34516B1/fr unknown
- 2011-09-06 PL PL11751910T patent/PL2614063T3/pl unknown
- 2011-09-06 HU HUE11751910A patent/HUE028771T2/en unknown
- 2011-09-06 US US13/822,175 patent/US9255100B2/en not_active Expired - Fee Related
- 2011-09-06 MX MX2013002713A patent/MX2013002713A/es active IP Right Grant
- 2011-09-06 ES ES11751910.8T patent/ES2568220T3/es active Active
- 2011-09-06 JP JP2013527575A patent/JP5824050B2/ja not_active Expired - Fee Related
- 2011-09-06 HR HRP20160360TT patent/HRP20160360T1/hr unknown
- 2011-09-06 BR BR112013005679A patent/BR112013005679A2/pt not_active IP Right Cessation
- 2011-09-06 AP AP2013006790A patent/AP3607A/xx active
- 2011-09-06 CA CA2810755A patent/CA2810755A1/en not_active Abandoned
- 2011-09-06 RS RS20160221A patent/RS54661B1/sr unknown
- 2011-09-06 EP EP11751910.8A patent/EP2614063B1/en active Active
- 2011-09-06 NZ NZ607904A patent/NZ607904A/en not_active IP Right Cessation
- 2011-09-06 CU CUP2013000033A patent/CU24187B1/es active IP Right Grant
- 2011-09-06 MY MYPI2013700375A patent/MY185139A/en unknown
- 2011-09-06 PE PE2013000392A patent/PE20131164A1/es not_active Application Discontinuation
- 2011-09-06 PH PH1/2013/500454A patent/PH12013500454A1/en unknown
- 2011-09-07 SA SA111320735A patent/SA111320735B1/ar unknown
- 2011-09-08 UY UY0001033598A patent/UY33598A/es unknown
- 2011-09-09 AR ARP110103294A patent/AR082946A1/es unknown
2013
- 2013-03-05 IL IL225058A patent/IL225058A/en active IP Right Grant
- 2013-03-07 ZA ZA2013/01756A patent/ZA201301756B/en unknown
- 2013-03-08 EC ECSP13012752 patent/ECSP13012752A/es unknown
- 2013-03-08 CR CR20130102A patent/CR20130102A/es unknown
- 2013-03-08 CO CO13047157A patent/CO6720961A2/es active IP Right Grant
- 2013-03-08 DO DO2013000054A patent/DOP2013000054A/es unknown
2016
- 2016-04-12 CY CY20161100294T patent/CY1117352T1/el unknown

Also Published As

Publication number	Publication date
CN103370318B (zh)	2016-04-20
AP2013006790A0 (en)	2013-04-30
DOP2013000054A (es)	2013-07-31
CR20130102A (es)	2013-04-17
ZA201301756B (en)	2016-06-29
AU2011298844B2 (en)	2015-02-19
CU20130033A7 (es)	2013-08-29
TWI541243B (zh)	2016-07-11
AP3607A (en)	2016-02-26
AU2011298844A1 (en)	2013-03-28
SI2614063T1 (sl)	2016-05-31
EP2614063A1 (en)	2013-07-17
IL225058A (en)	2017-03-30
HK1187623A1 (zh)	2014-04-11
EA023420B1 (ru)	2016-06-30
US20130338133A1 (en)	2013-12-19
ECSP13012752A (es)	2014-01-31
UY33598A (es)	2012-04-30
KR20140032337A (ko)	2014-03-14
SG188417A1 (en)	2013-04-30
HUE028771T2 (en)	2016-12-28
CO6720961A2 (es)	2013-07-31
SA111320735B1 (ar)	2015-10-21
EA201390339A1 (ru)	2013-09-30
BR112013005679A2 (pt)	2016-05-03
MA34516B1 (fr)	2013-09-02
ME02389B (me)	2016-09-20
NZ607904A (en)	2015-02-27
WO2012032031A1 (en)	2012-03-15
CY1117352T1 (el)	2017-04-26
HRP20160360T1 (hr)	2016-05-06
PL2614063T3 (pl)	2016-06-30
CU24187B1 (es)	2016-07-29
JP5824050B2 (ja)	2015-11-25
DK2614063T3 (en)	2016-04-18
US9255100B2 (en)	2016-02-09
CN103370318A (zh)	2013-10-23
TW201211049A (en)	2012-03-16
ES2568220T3 (es)	2016-04-28
PE20131164A1 (es)	2013-10-30
MY185139A (en)	2021-04-30
AR082946A1 (es)	2013-01-23
MX2013002713A (es)	2013-05-22
CA2810755A1 (en)	2012-03-15
RS54661B1 (sr)	2016-08-31
EP2614063B1 (en)	2016-01-13
JP2013537174A (ja)	2013-09-30

Publication	Publication Date	Title
PH12013500454A1 (en)	2013-04-29	Substituted imidazopyridazines
MY168413A (en)	2018-11-09	Amino-substituted imidazopyridazines
PH12021550792A1 (en)	2021-12-13	2-(morpholin-4-yl)-1,7-naphthyridines
TN2015000371A1 (en)	2017-01-03	Substituted imidazopyridazines
PH12016501581A1 (en)	2017-02-06	Benzimidazol-2-amines as midh1 inhibitors
PH12016501807A1 (en)	2016-11-21	Novel compounds
TN2014000254A1 (en)	2015-09-30	Substituted triazolopyridines and their use as ttk inhibitors
PH12016500054A1 (en)	2016-04-04	Substituted pyrazolo-pyridinamines
PH12017501133A1 (en)	2017-11-27	Pyrazolopyridinamines
JO3040B1 (ar)	2016-09-05	ترايازولوبيريدينات
CR20200057A (es)	2020-06-16	Dihidrooxadiazinonas
PH12016500931A1 (en)	2016-06-27	Thienopyrimidines as mknk1 and mknk2 inhibitors
PH12016501932A1 (en)	2016-12-19	Amido-substituted azole compounds
WO2010051933A3 (en)	2010-07-15	Substituted sulphonamido phenoxybenzamides
WO2010051935A3 (en)	2010-07-15	Substituted amido phenoxybenzamides
PH12016501814A1 (en)	2016-11-07	Inhibitors of the wnt signalling pathways
TN2014000091A1 (en)	2015-07-01	Amino-substituted imidazopyridazines
TN2013000099A1 (en)	2014-06-25	Substituted imidazopyridazines
MA39762A (fr)	2017-01-25	Nouveaux composés